Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00712504 · ClinicalTrials.gov registry record · Phase 1
Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT00712504 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 49 participants.
The verdict
NCT00712504, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
This study is determining the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel (Taxotere). Several dosing regimens will be tested in patients with advanced solid tumors, including non small cell lung cancer.
Interventions
- DRUG docetaxel
- DRUG sunitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2004-07 |
| Est. Completion | 2007-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00712504
The ClinicalTrials.gov registry entry for NCT00712504 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT00712504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00712504 about?
NCT00712504 is a clinical study titled "Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer". This study is determining the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel (Taxotere). Several dosing regimens will be tested in patients with advanced solid tumors, including non small cell lung cancer.
What is the current status of trial NCT00712504?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2004-07. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00712504?
The interventions under investigation include: docetaxel (DRUG), sunitinib (DRUG).
Who is sponsoring clinical trial NCT00712504?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.